Celgene Corp (CELG) 105.49 $CELG Celgene Corporation to

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Celgene Corp (CELG) 105.49 $CELG

Celgene Corporation to Webcast at Upcoming Investor Conferences and R&D Deep Dive in September
BusinessWire - Mon Aug 29, 6:30AM CDT
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences and at an R&D deep dive in September where Celgene management will provide an overview of the Company. The conferences and R&D deep dive will be webcast live and the webcasts will be available in the Investor Relations section of the Company's website at www.celgene.com.
CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)

Research Report on Biotech Equities -- Celgene, Sarepta Therapeutics, MannKind, and Opko Health
PR Newswire - Wed Aug 24, 6:35AM CDT
Stock-Callers.com has on its radar four Biotech stocks, namely: Celgene Corp. (NASDAQ: CELG), Sarepta Therapeutics Inc. (NASDAQ: SRPT), MannKind Corp. (NASDAQ: MNKD), and Opko Health Inc. (NASDAQ: OPK). According to Transparency Market Research, the global white biotechnology market will grow at a CAGR of 4.5% over the period between 2016 and 2024. White biotechnology, or industrial biotechnology, comprises all the biotechnology uses related to industrial processes. Learn more about these stocks by accessing their free research reports at:
OPK: 9.33 (+0.04), SRPT: 26.89 (+0.33), MNKD: 0.74 (unch), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)

Look for Shares of Celgene to Potentially Pullback after Yesterday's 1.71% Rise
Comtex SmarTrend(R) - Mon Aug 22, 12:22PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.53 to a high of $114.47. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $112.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 105.49 (-0.88)

SmarTrend Watching for Potential Pullback in Shares of Celgene After 1.71% Gain
Comtex SmarTrend(R) - Mon Aug 22, 12:20PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.53 to a high of $114.47. Yesterday, the shares gained 1.7%, which took the trading range above the 3-day high of $112.95 on volume of 1.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
CELG: 105.49 (-0.88)

ETFs in Focus on Pfizer's Medivation Acquisition
Zacks Equity Research - Zacks Investment Research - Mon Aug 22, 11:01AM CDT
The pharma giant, Pfizer (PFE) announced to acquire Medivation (MDVN) for $14 billion.
IHE: 147.95 (-0.83), MDVN: 80.85 (-0.08), GILD: 76.89 (-0.53), MRK: 62.98 (+0.08), PFE: 34.77 (+0.09), FHLC: 34.54 (+0.03), SNY: 39.18 (+0.77), VHT: 133.16 (+0.19), XLV: 72.65 (+0.08), CELG: 105.49 (-0.88)

Under Armour trade offers a 5% return in 32 days, or find similar option trades on Endo International, Sears Holdings, Celgene, and Barrick Gold Corporation
PR Newswire - Mon Aug 15, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for ABX, CELG, ENDP, SHLD, and UA.
UA: 38.56 (-1.19), ENDP: 19.82 (-0.41), ABX: 18.16 (+0.36), SHLD: 13.33 (-0.16), CELG: 105.49 (-0.88)

Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene, to Join Sorrento as Chief Medical Officer and President of Clinical Development
PR Newswire - Mon Aug 15, 8:00AM CDT
Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento", an antibody-centric, clinical-stage biopharmaceutical company developing new treatments for cancer, pain management, inflammation and autoimmune diseases, today announced that Dr. Jerome Zeldis, M.D., Ph.D., former Chief Medical Officer of Celgene Corporation (NASDAQ: CELG; "Celgene", has been appointed to the position of Chief Medical Officer and President of Clinical Development.
SRNE: 6.73 (-0.03), CELGZ: 1.18 (+0.05), CELG: 105.49 (-0.88)

Stock Market News for August 09, 2016
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 9:10AM CDT
Despite strong crude rally, major benchmarks closed in the red on Monday on the back of declines in healthcare stocks
PFE: 34.77 (+0.09), XOM: 87.42 (+0.58), AMGN: 169.77 (-0.36), PDCO: 46.89 (+0.86), COP: 40.92 (+0.32), BMY: 56.35 (-0.41), SLB: 78.55 (-0.41), CELG: 105.49 (-0.88), AGN: 235.96 (-1.80), JNJ: 119.32 (+0.24), GILD: 76.89 (-0.53), TSO: 74.55 (+1.24), MRK: 62.98 (+0.08), MRO: 15.49 (+0.38), CVX: 100.93 (+0.72)

Look for Shares of Celgene to Potentially Rebound after Yesterday's 1.80% Sell Off
Comtex SmarTrend(R) - Mon Aug 08, 11:54AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.80 to a high of $115.53. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $113.86 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 105.49 (-0.88)

After Yesterday's Decline of 1.80%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Mon Aug 08, 11:52AM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $112.80 to a high of $115.53. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $113.86 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
CELG: 105.49 (-0.88)

Next Support Level for Celgene (CELG) is $113.72
Comtex SmarTrend(R) - Mon Aug 08, 9:21AM CDT
Celgene (NASDAQ:CELG) has opened bearishly below the pivot of $116.26 today and has reached the first level of support at $114.63. Analysts will be watching for a cross of the next downside pivot targets of $113.72 and $111.18.
CELG: 105.49 (-0.88)

BetterInvesting Magazine Releases October Stock To Study And Undervalued Stock Choices For Investors' Informational And Educational Use
PR Newswire - Fri Aug 05, 3:15PM CDT
The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Celgene Corporation (NDQ: CELG) as its October 2016 "Stock to Study" and Amgen Inc. (NDQ: AMGN), as its October 2016 "Undervalued Stock" for investors' informational and educational use.
AMGN: 169.77 (-0.36), CELG: 105.49 (-0.88), CELGZ: 1.18 (+0.05)

Agios (AGIO) Q2 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Fri Aug 05, 10:10AM CDT
Agios Pharmaceuticals (AGIO) reported a wider-than-expected second-quarter 2016 loss of $1.47 per share.
GERN: 2.75 (+0.02), AGIO: 36.35 (-0.39), ANIK: 47.89 (-0.05), CELG: 105.49 (-0.88)

Juno (JUNO) Q2 Loss Wider-than-Expected, Focus on Pipeline
Arpita Dutt - Zacks Investment Research - Fri Aug 05, 6:19AM CDT
Although Juno's (JUNO) Q2 loss was wider-than-expected, investor focus primarily remains on the company's pipeline.
GERN: 2.75 (+0.02), JUNO: 28.44 (-0.85), CELG: 105.49 (-0.88), NVS: 79.38 (+1.11)

Covered Call reports for Micron, The Blackstone Group, Celgene, AIG and NetEase Inc. include trade ideas that offer returns of 20% or more!
PR Newswire - Thu Aug 04, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for AIG, BX, CELG, MU, and NTES.
MU: 16.70 (+0.06), NTES: 214.91 (-1.00), BX: 26.88 (-0.05), AIG: 59.86 (+0.45), CELG: 105.49 (-0.88)

Upgrade Alert for Celgene (CELG)
Comtex SmarTrend(R) - Thu Aug 04, 3:19AM CDT
Celgene (NASDAQ:CELG) was upgraded from Neutral to Buy at BTIG today. The stock closed yesterday at $116.14 on volume of 6.3 million shares, above average daily volume of 4.7 million. Celgene share prices have moved between a 52-week high of $140.72 and a 52-week low of $92.98 and closed yesterday at 25% above that low price at $116.14 per share. Over the last five market days, the 200-day moving average (MA) has gone down 0.6% while the 50-day MA has remained constant.
CELG: 105.49 (-0.88)

Will Agios (AGIO) Disappoint Estimates in Q2 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue Aug 02, 10:23AM CDT
Agios Pharmaceuticals (AGIO), which is set to report second-quarter 2016 results on Aug 4, had posted a positive surprise of 11.59% last quarter.
ICPT: 150.74 (+3.92), AGIO: 36.35 (-0.39), EXEL: 11.54 (+0.19), CELG: 105.49 (-0.88)

Juno (JUNO) Q2 Earnings: Will the Stock Disappoint?
Arpita Dutt - Zacks Investment Research - Tue Aug 02, 5:49AM CDT
With no approved products in its portfolio, focus will remain on Juno's (JUNO) pipeline and cash burn.
RPTP: 7.28 (+0.04), TECH: 106.88 (+0.35), JUNO: 28.44 (-0.85), CELG: 105.49 (-0.88)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

USPS Honors 150 Years of the U.S. Coast Guard Academy

Updated Category News Views 0

Honoring Tradition and Service The good ol’ U.S. Postal Service is at it again, giving a tip of the hat to a slice of American military heritage. This time, they’re putting out a new stamp to celebrate the 150th anniversary of the U.S. Coast Guard Academy. And you know where they did the honors? Right there on Custom House Pier in New London, Connecticut, a place that...

Continue Reading
Pizza: The Unlikely Symbol of Universal Togetherness

Updated Category News Views 0

Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...

Continue Reading
OneOdio Showcases Innovation at IFA 2026 in Berlin

Updated Category News Views 1

Echoes from Berlin IFA 2026 in Berlin was a cacophony of innovation, as OneOdio wrapped up its showcase with a bang. Boasting interactive activities and live DJ sets, the event echoed OneOdio's drive to meld advanced audio technology with the pulsating needs of music pros and everyday listeners. You couldn’t miss the excitement in the air at Booth 217. Tech Unplugged:...

Continue Reading
New 2027 Jeep Wrangler JL-2A: A Blast from the Past

Updated Category News Views 3

Revisiting a Prized Legacy: The 2027 Jeep Wrangler JL-2A Sometimes, what’s new is really just a nod to what’s old—and nowhere is this more so than with the 2027 Jeep Wrangler JL-2A. In the grand parade of automotive history, Jeep's latest creation is more than just a vehicle; it's a time machine that cruises on its historic lineage while strapping on all the modern...

Continue Reading
Larry Ellison's Moves Signal Confidence in Oracle's Future

Updated Category News Views 2

Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...

Continue Reading
Damp or Dry: The Battle for Healthy Air in Colorado

Updated Category News Views 3

The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 8

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading
Ajman Spotlights Tourism at Arabian Travel Market 2026

Updated Category News Views 2

Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...

Continue Reading
Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 5

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 3

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading

Top 5 Most Recently Viewed Articles

Fenix24 and Partners Recognized for Outstanding Cybersecurity

Updated Category News Views 306

Fenix24 and Partners Shine in Global Cybersecurity Awards Fenix24, a leading cyber disaster recovery firm, has affirmed its position as a market leader following recent recognitions in the cybersecurity sector. This award from the Cyber Defense Magazine showcases Fenix24’s commitment to setting new standards in breach recovery and incident response, fostering...

Continue Reading
Savara Inc. Shareholders: Your Chance to Join the Legal Battle

Updated Category News Views 207

Understanding the Opportunity for Action Investors holding shares of Savara Inc. (NASDAQ: SVRA) may find an important opportunity to engage in a class action lawsuit. The law firm spearheading this effort, known for its focus on shareholder rights, is reaching out to those affected by possible misstatements made by the company. What Led to the Class Action Lawsuit? The...

Continue Reading
Brennan Investment Group Expands Portfolio with Major Acquisition

Updated Category News Views 415

Brennan Investment Group's Strategic Move in the Industrial Market Brennan Investment Group has made a significant stride in the industrial real estate sector with its recent acquisition of an expansive industrial campus previously owned by Innovex. This strategic move marks one of the largest transactions in the region this year, emphasizing the group's commitment to...

Continue Reading
ViaSat Faces Competition From Starlink in Connectivity Market

Updated Category News Views 240

ViaSat's Position in the Market Amid Starlink's Rise Deutsche Bank recently reaffirmed its Hold rating on ViaSat (NASDAQ: VSAT), setting a target price of $22. This update comes after noticeable shifts in the inflight connectivity market, particularly with Starlink emerging as a formidable competitor by securing contracts for about 2,500 aircraft, which includes both...

Continue Reading
Stellantis NV: Short Interest Shift Sparks Investor Sentiment Questions

Updated Category News Views 231

Stellantis NV's (NYSE:STLA) short interest saw a notable drop of 13.81% since its last report, now standing at 44.96 million shares sold short, or about 1.56% of all tradable shares. Sounds like good news, right? But hang on—this isn't just a free pass to pop the champagne. When we talk short interest, we're peeling back layers on market sentiment that can turn on a...

Continue Reading